Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.

By M. Cavo, S. Rajkumar, S. Hayman, M. Lacy, A. Dispenzieri, S. Geyer, B. Kabat, S. Zeldenrust, Shaji K. Kumar, P. Greipp and 6 more. Blood, 2005

674 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. (2010, neutral): “Median age, y (range) 58 (22-86) 59 (22-86)”
Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management (2020, background): “The initial impact came from the introduction of thalidomide,(50) bortezomib,(51) and lenalidomide.(52,53) In the last decade, carfilzomib, pomalidomide, panobinostat, ixazomib, elotuzumab, daratumumab, isatuximab, and selinexor have been approved by”
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets (2007, background): “For example, the addition of dexamethasone, which induces caspase 9-dependent apoptosis, to lenalidomide, which activates caspase 8-dependent apoptosis, triggers dual apoptotic signalling in vitro and improves clinical responses in multiple myelom”
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management (2022, background): “The initial impact came from the introduction of thalidomide,(56) bortezomib,(57) and lenalidomide.(58,59) In the last decade, carfilzomib, pomalidomide, ixazomib, elotuzumab, daratumumab, isatuximab, selinexor, belantamab mafodotin, and chimeric antigen receptor-T (CAR-T) cell therapies have been a”